Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human cytomegalovirus (HCMV) surface glycoproteins are essential structural components of the viral envelope that facilitate the virus's entry into a wide range of human cells, including epithelial, endothelial, and fibroblast cells (Vanarsdall & Johnson, 2017). The most prominent of these are glycoprotein B (gB), which serves as the primary viral fusogen, and the gH/gL complexes, which include the trimeric (gH/gL/gO) and pentameric (gH/gL/UL128/UL130/UL131A) assemblies (Ryckman et al., 2008). These glycoproteins mediate initial attachment to host cell surface receptors, such as heparan sulfate proteoglycans and specific protein receptors like PDGFR-alpha or Neuropilin-1, triggering the fusion of the viral envelope with the host cell membrane (Kabanova et al., 2016). As the primary targets for the host immune response, these glycoproteins are the focus of therapeutic interventions, including neutralizing monoclonal antibodies and prophylactic vaccines (Plotkin, 2015). Inhibiting these proteins prevents the initiation of the viral life cycle, making them critical targets for managing CMV-related diseases in immunocompromised patients and preventing congenital transmission (FDA, CytoGam Label). The complexity of these glycoprotein complexes allows the virus to utilize different entry pathways depending on the cell type, which presents a challenge for drug design. Neutralizing antibodies often target the pentameric complex to block entry into epithelial and endothelial cells, while antibodies against gB can block entry into all cell types. Current research focuses on developing multi-specific antibodies or vaccines that elicit a broad response against multiple glycoprotein components to ensure comprehensive protection.
Neutralization of viral entry by blocking attachment to host receptors or inhibiting the membrane fusion process.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human cytomegalovirus surface glycoprotein (HCMV glycoprotein) (HCMV glycoproteins).